Matches 1 - 50 out of 167 1 2 3 4 >


Match Document Document Title
US20110300212 Pharmaceutical Formulation  
The present invention is directed to pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a...
US20160338978 Organic Compounds  
The present invention provides various pharmaceutical compositions comprising an S1P receptor modulator, e.g. an S1P receptor agonist. In one aspect, there is provided a pharmaceutical composition...
US20160128945 CONTROLLED RELEASE PREPARATION  
A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the...
US20160113880 Once Daily Formulations of Tetracyclines  
Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent...
US20150366803 NRF2 Screening Assays and Related Methods and Compositions  
Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The...
US20150290138 Crush resistant delayed-release dosage forms  
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one...
US20150030675 Controlled Release Dosage Forms  
The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55°...
US20140199390 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER  
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of...
US20140112984 Crush resistant delayed-release dosage forms  
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one...
US20120141583 ALCOHOL RESISTANT DOSAGE FORMS  
Opioid controlled release formulation resistant to alcohol extraction of the opioid.
US20110059169 Method and Composition for Administering an NMDA Receptor Antagonist to a Subject  
The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
US20100272796 SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION  
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into...
US20100272795 SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION  
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into...
US20090074859 SOLID CARRIERS FOR IMPROVED DELIVERY OF ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS  
The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one...
US20080311187 CRUSH RESISTAN DELAYED-RELEASE DOSAGE FORM  
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one...
US20060115527 CONTROLLED RELEASE PREPARATION  
Controlled release preparations and capsules are provided. Also provided are emulsions and suspensions, including compositions and methods of manufacturing controlled release capsules, where the...
US20140147499 ABUSE-PROOFED ORAL DOSAGE FORM  
The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which...
US20130287846 ABUSE-PROOFED ORAL DOSAGE FORM  
The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which...
US20120070494 Treatment for Attention-Deficit Hyperactivity Disorder  
A method for treating Attention Deficit/Hyperactivity Disorder (ADHD) in humans and the symptoms associated therewith, inattentiveness, and hyperactivity with impulsivity, using eltoprazine and...
US20120021053 CONTROLLED RELEASE AND TASTE-MASKING ORAL PHARMACEUTICAL COMPOSITION  
Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic,...
US20110150989 Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans  
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form...
US20110091542 BACLOFEN AND R-BACLOFEN GASTRORETENTIVE DRUG DELIVERY SYSTEMS  
A biodegradable, multi-layered controlled release gastroretentive baclofen or R-baclofen dosage form which is optionally divided into a first dosage of baclofen or R-baclofen for immediate release...
US20110008425 Treatment for Attention-Deficit Hyperactivity Disorder  
A method for treating Attention Deficit/Hyperactivity Disorder (ADHD) in humans and the symptoms associated therewith, inattentiveness, and hyperactivity with impulsivity, using eltoprazine and...
US20100062058 Delayed Release Formulations for Oral Administration of a Polypeptide Therapeutic Agent and Methods of Using Same  
The invention provides compositions containing polypeptides, including therapeutic polypeptides such as interleukin-11, that are suitable for oral administration.
US20090304789 NOVEL TOPIRAMATE COMPOSITIONS AND AN ESCALATING DOSING STRATEGY FOR TREATING OBESITY AND RELATED DISORDERS  
The present invention is drawn to novel topiramate compositions as well as methods for treating obesity and related conditions, including conditions associated with and/or caused by obesity per...
US20090104261 Treatment for Attention-Deficit Hyperactivity Disorder  
A method for treating Attention Deficit/Hyperactivity Disorder (ADHD) in humans and the symptoms associated therewith, inattentiveness, and hyperactivity with impulsivity, using eltoprazine and...
US20080181941 ORALLY ADMINISTRABLE OPIOID FORMULATIONS HAVING EXTENDED DURATION OF EFFECT  
Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for...
US20160038411 PULSATILE GASTRIC RETENTIVE DOSAGE FORMS  
Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric retentive dosage forms that achieve release of the therapeutic agent...
US20150010624 CARBIDOPA/LIPODOPA GASTRORETENTIVE DRUG DELIVERY  
A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more...
US20100166855 ORAL INSULIN COMPOSITION AND METHODS OF MAKING AND USING THEREOF  
A method of lowering blood glucose in a mammal includes orally administering a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood...
US20090148518 Pharmaceutical Formulations  
The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection moulding of single or multi-component pharmaceutical dosage...
US20070154542 Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors  
The present disclosure provides enteric coated capsules and orally dissolving films comprising non-steroidal anti-inflammatory drugs and acid inhibitors, as well as methods of treating treatment...
US20160220553 COMPOSITIONS AND METHODS FOR TREATMENT OF SYMPTOMS IN PARKINSON'S DISEASE PATIENTS  
The invention provides dosage forms and methods utilizing nicotine to treat symptoms of a neurologic disorder. In some embodiments, the invention provides compositions for treatment of gait and...
US20140154314 DELAYED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF  
Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition...
US20130273154 Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes  
The invention provides pharmaceutical compositions, methods for the treatment of, and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic...
US20130224292 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20130017259 Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients  
The invention provides dosage forms and methods utilizing nicotine to treat symptoms of a neurologic disorder. In some embodiments, the invention provides compositions for treatment of gait and...
US20170151186 AMANTADINE COMPOSITIONS AND METHODS OF USE  
Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine...
US20140134243 Compositions for the Treatment of CNS-Related Conditions  
The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine...
US20140030323 CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION  
The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present...
US20100159001 Extended-Release Pharmaceutical Formulations  
The present invention provides matrix-forming, sustained-release pharmaceutical formulations comprising four primary components: i) an effective amount of at least one drug substance; ii) at least...
US20090196921 Compositions Methods and Kits For Enhancing Immune Response To A Respiratory Condition  
Disclosed herein are compositions for treating a respiratory condition, preferably by enhancing immune response in a mammal, the compositions including a therapeutic amount of a probiotic strain...
US20080020018 Combination Products  
A pharmaceutical formulation comprises a plurality of seamless minicapsules having a diameter of from 0.5 mm to 5 mm, at least some of the minicapsules containing a methyxanthine as one active...
US20120244216 COATED PHARMACEUTICAL CAPSULE DOSAGE FORM  
Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at...
US20100239666 Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding  
The invention relates to a process for producing mouldings by injection moulding the steps in the process being a) melting and mixing of a (meth)acrylate copolymer composed of from 85 to 98% by...
US20170151188 COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE  
Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine....
US20160324852 COMPOSITIONS AND METHODS OF TREATING A NEURODEGENERATIVE DISEASE  
The present application relates to new uses of 5-HT6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or pharmaceutically acceptable salts, hydrates, solvates, or...
US20140308346 COMBINATION THERAPY FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY  
The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in...
US20120135074 High-Strength Testosterone Undecanoate Compositions  
The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the present...
US20070269505 Tamper Resistant Co-Extruded Dosage Form Containing An Active Agent And An Adverse Agent And Process Of Making Same  
The present invention relates to co-extruded pharmaceutical compositions and dosage forms including an active agent, such as an opioid agonist, and an adverse agent, such as an opioid antagonist....

Matches 1 - 50 out of 167 1 2 3 4 >